✦ LIBER ✦

Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias

✍ Scribed by Jabbour, Elias; El Ahdab, Samih; Cortes, Jorge; Kantarjian, Hagop

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical Pharmacokinetics of the BCR–ABL

✍ Tanaka, C; Yin, O Q P; Sethuraman, V; Smith, T; Wang, X; Grouss, K; Kantarjian, 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 202 KB

BCR-ABL Tyrosine Kinase Inhibitors for C

✍ Schiffer, Charles A. 📂 Article 📅 2007 🏛 Massachusetts Medical Society 🌐 English ⚖ 219 KB

New BCR-ABL tyrosine kinase inhibitors f

✍ Jame Abraham 📂 Article 📅 2007 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 114 KB

Nilotinib: A New Tyrosine Kinase Inhibit

✍ Anthony Jarkowski; Richard P. Sweeney 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB

Importance of adherence to BCR-ABL tyros

✍ de Almeida, Maria Helena; Fogliatto, Laura; Couto, Dulce 📂 Article 📅 2014 🏛 SciELO 🌐 English ⚖ 170 KB

The Second Generation of BCR-ABL Tyrosin

✍ Tetsuzo Tauchi; Kazuma Ohyashiki 📂 Article 📅 2006 🏛 Carden Jennings Publishing 🌐 English ⚖ 734 KB